Margaret Taggett Reports 6.6% Stake in Biora Therapeutics
The Connecticut-based investor now holds sole voting and dispositive power over nearly 300,000 shares.
August 05, 2025

Biora Therapeutics Gains New Large Shareholder as Margaret Taggett Reports 6.6% Ownership
A new investor has stepped into the spotlight at Biora Therapeutics. Margaret Ellen Taggett has taken a 6.6% equity stake in the company, according to a Schedule 13G filed with the SEC on August 4. That translates to 297,000 shares of common stock, all under her sole voting and dispositive control.
The disclosure is based on Biora’s reported 4.52 million outstanding shares, and reflects a threshold that requires investors to publicly report their positions once they cross 5%. This filing falls under Rule 13d-1(c), which applies to individuals and institutions that own large stakes but aren’t trying to influence control of the company.
Taggett isn’t filing as part of a group. She’s not representing a fund, a parent company, or any affiliated entity—this is a direct holding, made independently. The shares aren’t tied to any partnership or proxy activity, and the filing confirms there’s no broader strategic intent behind the stake beyond standard investment purposes.
What’s notable here is the structure of the position. Every share is under her direction—voting rights, disposition, all of it. That level of control can matter in a company of Biora’s size, especially as shareholders track who has meaningful say over company decisions, even in a passive capacity.
Biora, headquartered in San Diego, is focused on targeted drug delivery technologies. While this filing doesn’t reveal Taggett’s investment rationale, it does signal her interest in the company’s trajectory. Whether this is a long-term hold or part of a broader investment strategy remains to be seen, but the 6.6% stake now puts her among the company’s most substantial individual shareholders.
For public companies like Biora, changes in shareholder composition matter. They can signal shifting sentiment or new attention on a company’s direction. Investors and analysts watching Biora will likely keep an eye on whether this position grows—or leads to further activity in the months ahead.
Share
Read More Articles